Trial
NCT05037669
Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Pennsylvania
Collaborators
—
Condition
Acute Lymphoblastic Leukemia
Intervention
PACE CART19
Why stopped
No available investigational product
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-22